Stockscreener 앱 받기
3.94
2.72%
-0.11
시장 영업 전:
4.20
0.26
+6.60%
전일 마감가:
$4.05
열려 있는:
$4.06
하루 거래량:
892.23K
Relative Volume:
0.64
시가총액:
$449.34M
수익:
$884.00K
순이익/손실:
$-103.64M
주가수익비율:
-2.8256
EPS:
-1.3944
순현금흐름:
$-95.45M
1주 성능:
-1.01%
1개월 성능:
+0.25%
6개월 성능:
+67.66%
1년 성능:
+45.93%
1일 변동 폭
$3.90
$4.15
1주일 범위
$3.90
$4.34
52주 변동 폭
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.94 | 461.89M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Piper Sandler | Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Surprise History - thelegaladvocate.com
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Perspective Therapeutics shareholders approve directors and governance items - TipRanks
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor - Stock Titan
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Loss Narrows Sharply, Stock Gains 2.84%Profitability Analysis - thelegaladvocate.com
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) - The Globe and Mail
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative
Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo
CATX: VMT-α-NET shows high efficacy and safety, with phase III readiness and broad pipeline progress - TradingView
CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics doses first patients in two trial cohorts By Investing.com - Investing.com Australia
Perspective Therapeutics doses first patients in two trial cohorts - Investing.com UK
Perspective Therapeutics (CATX) Begins Patient Dosing in New Cli - GuruFocus
Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors - marketscreener.com
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors - Quiver Quantitative
Two cancer radiopharmaceuticals start dosing patients in early trials - Stock Titan
CATX Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX) - Stock Titan
RBC Capital reiterates Outperform on Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
RBC Capital reiterates Outperform on Perspective Therapeutics stock - Investing.com
MSN Money - MSN
Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics earnings beat by $0.05, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss - ChartMill
Perspective Therapeutics 1Q Loss/Shr 25c >CATX - Moomoo
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 - GuruFocus
Perspective Therapeutics: Q1 Earnings Snapshot - KTVB
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances - TipRanks
Perspective Therapeutics Q1 net loss widens as grant revenue drops - TradingView
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - The Manila Times
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027 - Stock Titan
Perspective Therapeutics: $271M cash to advance 3 cancer trials - Stock Titan
Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Number of shareholders of Perspective Therapeutics, Inc. – DUS:AAJ0 - TradingView
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Transcript : Perspective Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
1.94%
자본화:
|
볼륨(24시간):